PLA2G7 and metabolic dysfunction-associated steatohepatitis: Furthermore, lysoPC, particularly the 16:0 lysoPC, a main product of Lp‐PLA2, was associated with several diseases, including NASH,228 DR,37 CAVD,274 and CNS diseases.14 Therefore, we assume that alterations in the lysoPC level, the ratio between Lp‐PLA2 and lysoPC, or even the proportion among Lp‐PLA2, lysoPC, and oxLDL may be an alternative monitoring metric for determining the role of Lp‐PLA2 in various diseases.